In vivo, when engrafted into immunodeficient NSG mice, GFP+ miR-142 KD CD34+ CML cells produced higher blood and BM engraftment rates (i.e., human CD45+GFP+ cells) as compared with GFP+ miR-142 wt CD34+ controls (2.8% vs 0.6% in BM four weeks after transplantation, p < 0.0001; Supplementary Fig. 5g), thereby supporting that increased “stemness” associated with the miR-142 deficit. The gene discussed is PTPRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.